TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
News|Articles|October 27, 2023
Daily Dose: Novel Intranasal COVID-19 Vaccine Induces Strong Immune Response
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 13, 2023, we reported on findings presented at IDWeek 2023, held October 11-15 in Boston, MA.
The study
A randomized, placebo-controlled phase 1 CDX-CoV-001 clinical trial of CoviLivTM, a novel vaccine candidate that is derived from SARS-CoV-2/Wuhan that is engineered to genetically convert the virus from disease-causing pathogen to stable, safe live-attenuated vaccine. CDX-CoV-001 was a dose escalation study of CoviLiv used a primary vaccination series in healthy adults to establish the vaccine's safety and tolerability.
Data presented at the meeting highlighted the immune response to CoviLiv among participants in the study cohort that received the highest dose of 5x106 pfu (n=6/group).
Investigators characterized humoral immune response on days 1, 29, and 57 and analyzed T-cell functionality on days 1 and 36.
Findings
On post-vaccination study day 57, after 2 doses of the intranasal vaccine, researchers reported a greater than 2-fold increase in spike-specific IgG among all participants, with a geometric mean fold rise of 19.5.
Neutralizing antibodies at day 57 were induced 2.6-fold based on microneutralization assay and by 4.9-fold using pseudovirus neutralization assay.
On post-vaccination day 36, after restimulation with a variety of SARS-CoV-2 peptides to mimic virus strains and variants, T-cell response increased by 2.5-fold in the study cohort receiving 1 dose and by nearly double that, 4.5-fold, in the 2-dose cohort.
Authors' comment
“The study findings provide a glimpse into what could be the next generation of COVID-19 vaccines that provide differentiated protection to more people. Vaccine administration by nose and easier storage can increase access to vaccinations for underserved areas across the world."
Click here for more details.
Advertisement
Related to this article
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.
In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
3
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
4
More Frequent Physical Activity Linked to Fewer Perimenopause Symptoms in Global Study
5